Jie Wang, Yuehui Yin, Chengzhi Lu, Zhibing Lu, Jialu Hu, Yue Wang, Junbo Ge, Hong Jiang, Chen Yao, Xiaoyan Yan, Wei Ma, Xiaoyong Qi, Yi Dang, Shaoliang Chen, Jiancheng Zhu, Dongmei Wang, Chao Ding, Weimin Wang, Jian Liu, Yanbin Wang, Hui Li, Zhenhua Pan, Kaijun Cui, Chengzong Li, Xinjian Liang, Weijie Chen, Paul A Sobotka, JingJing Zhang, Murray Esler, Ningling Sun, Minglong Chen, Yong Huo
BACKGROUND: Previous trials of renal denervation (RDN) have been designed to investigate reduction of blood pressure (BP) as the primary efficacy endpoint using non-selective RDN without intraoperatively verified RDN success. It is an unmet clinical need to map renal nerves, selectively denervate renal sympathetic nerves, provide readouts for the interventionalists and avoid futile RDN. We aimed to examine the safety and efficacy of renal nerve mapping/selective renal denervation (msRDN) in patients with uncontrolled hypertension (HTN) and determine whether antihypertensive drug burden is reduced while office systolic BP (OSBP) is controlled to target level (<140 mmHg)...
June 2024: EClinicalMedicine